Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Certara (CERT)
NASDAQ:CERT
Holding CERT?
Track your performance easily
CERT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$10.35 - $19.87
Previous Close$10.93
Volume598.31K
Average Volume (3M)1.01M
Market Cap
$1.83B
Enterprise Value$1.84B
Total Cash (Recent Filing)$224.60M
Total Debt (Recent Filing)$307.83M
Price to Earnings (P/E)―
Beta1.67
Next Earnings
Nov 05, 2024EPS Estimate
$0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.49
Shares Outstanding160,888,754
10 Day Avg. Volume2,119,604
30 Day Avg. Volume1,009,624
Standard Deviation0.16
R-Squared0.19
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)1.68
Price to Sales (P/S)4.79
Price to Cash Flow (P/CF)44.40
P/FCF Ratio117.90
Enterprise Value/Market CapN/A
Enterprise Value/Revenue5.07
Enterprise Value/Gross Profit8.63
Enterprise Value/Ebitda1.45K
Forecast
1Y Price Target
$16.83Price Target Upside47.76% Upside
Rating ConsensusHold
Number of Analyst Covering8
Certara News
Bulls Say, Bears Say
Bulls Say
AcquisitionCertara acquires Chemaxon, expanding biosimulation platform into discovery.
EarningsTotal bookings increased 15% YoY, with software +17% YoY and services +14% YoY.
Product LaunchNotable product launches included CoAuthor, a GenAI based application for medical and regulatory writing, with management noting good interest.
Bears Say
EarningsAdjusted EBITDA decreased 19% YoY, representing margins of 28% vs. 36% YoY.
Market PerformanceDecelerating clinical trial initiations across 2022-2023, and more modest biopharma capital markets activity during the same timeframe create cautious near-term organic growth expectations.
RevenueCertara reported 2Q24 revenue of $93.3M, which was below both the estimate and consensus.
---
Ownership Overview
4.12% Insiders
29.12% Mutual Funds
53.67% Other Institutional Investors
13.08% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CERT FAQ
What was Certara’s price range in the past 12 months?
Certara lowest stock price was $10.35 and its highest was $19.87 in the past 12 months.
What is Certara’s market cap?
Currently, no data Available
When is Certara’s upcoming earnings report date?
Certara’s upcoming earnings report date is Nov 05, 2024 which is in 46 days.
How were Certara’s earnings last quarter?
Certara released its earnings results on Aug 06, 2024. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.103 by -$0.033.
Is Certara overvalued?
According to Wall Street analysts Certara’s price is currently Undervalued.
Does Certara pay dividends?
Certara does not currently pay dividends.
What is Certara’s EPS estimate?
Certara’s EPS estimate is $0.11.
How many shares outstanding does Certara have?
Certara has 160,888,750 shares outstanding.
What happened to Certara’s price movement after its last earnings report?
Certara reported an EPS of $0.07 in its last earnings report, missing expectations of $0.103. Following the earnings report the stock price went down -13.594%.
Which hedge fund is a major shareholder of Certara?
Among the largest hedge funds holding Certara’s share is Bridgewater Associates, LP. It holds Certara’s shares valued at 2M.
---
Certara Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$16.83 (47.76% Upside)
$16.83 (47.76% Upside)
Blogger Sentiment
Bullish
CERT Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 146.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 8.3%
Last 30 Days ▼ 8.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-21.81%
12-Months-Change
Fundamentals
Return on Equity
-7.35%
Trailing 12-Months
Asset Growth
-2.07%
Trailing 12-Months
Company Description
Certara
Certara Inc accelerate medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides proven modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trial, accelerate regulatory approval and increase patient access to medicines.
---
CERT Company Deck
---
CERT Earnings Call
Q2 2024
0:00 / 0:00
---
CERT Stock 12 Month Forecast
Average Price Target
$16.83
▲(47.76% Upside)
Technical Analysis
Best Analysts Covering CERT
1 Year
1 Year Success Rate
0/8 ratings generated profit
1 Year Average Return
-16.34%
reiterated a buy rating last month
Copying Michael Ryskin's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -16.34% per trade.
---